As misregulation of the p53–Mdm2 PPI is implicated in over 50 % of all human cancers, this interaction is the subject of a large number of studies, with the resulting wealth of knowledge making p53–Mdm2 a useful platform to showcase novel therapeutic design.[16]. This evidence concerns the gene MDM2 and cancer.